Selectively altering microbiota for immune modulation
AssigneeSNIPR Technologies Limited
InventorJasper Clube
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
Claims30
A method of treating or preventing sepsis or septic shock in a human or animal subject, the method comprising selective targeting of pathogenic host cells of a first bacterial or archaeal species, wherein the host cells are comprised by a microbiota in the subject, wherein the method comprising:
- a. contacting the microbiota with an engineered nucleic acid sequence for producing a host modifying (HM) crRNA, and
- b. producing the HM-crRNA in a host cell,
- wherein the HM-crRNA is operable with a Cas nuclease in the host cell to form a HM-CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system, and wherein the HM-crRNA comprises a sequence that is capable of hybridizing to a target sequence of the host cell to guide the Cas nuclease to the target sequence in the host cell, whereby the target sequence is modified by the HM-CRISPR/Cas system and the host cell is killed or growth of the host cell is reduced, thereby reducing the proportion of host cells in the microbiota.
A method of treating or preventing sepsis or septic shock in a human or animal subject, the method comprising selective targeting of pathogenic host cells, wherein the host cells are E. coli cells, wherein the host cells are comprised by a microbiota in the subject, wherein the method comprising:
- a. contacting the microbiota with an engineered nucleic acid sequence for producing a HM-crRNA, and
- b. producing the HM-crRNA in a host cell,
- wherein the HM-crRNA is operable with a Cas nuclease in the host cell to form a HM-CRISPR/Cas system, and wherein the HM-crRNA comprises a sequence that is capable of hybridizing to a target sequence of the host cell to guide the Cas nuclease to the target sequence in the host cell, whereby the target sequence is modified by the HM-CRISPR/Cas system and the host cell is killed or growth of the host cell is reduced thereby reducing the proportion of host cells in the microbiota;
- and
- wherein the microbiota is a kidney microbiota or urethra microbiota.
A method of treating or preventing sepsis or septic shock in a human or animal subject, the method comprising selective targeting of pathogenic host cells, wherein the host cells are Staphylococcus, Streptococcus, Mycobacterium, Haemophilus or Pseudomonas cells, wherein the cells are comprised by a microbiota in the subject, wherein the method comprising:
- a. contacting the microbiota with an engineered nucleic acid sequence for producing a HM-crRNA, and
- b. producing the HM-crRNA in a host cell,
- wherein the HM-crRNA is operable with a Cas nuclease in the host cell to form a HM-CRISPR/Cas system, and wherein the HM-crRNA comprises a sequence that is capable of hybridizing to a target sequence of the host cell to guide the Cas nuclease to the target sequence in the host cell, whereby the target sequence is modified by the HM-CRISPR/Cas system and the host cell is killed or growth of the host cell is reduced, thereby reducing the proportion of host cells in the microbiota;
- and
- wherein the microbiota is a lung microbiota.
Dependencies are inferred from the claim text.